About Immunocine Cancer Center
Spotlight
Elizabeth's Stage 4 Ovarian Healing Journey
Witness the extraordinary story of Babette, a stage 4 ovarian cancer warrior, as she embraces a groundbreaking journey with Immunocine clinic. Follow her remarkable path to remission filled with hope, innovation, and relentless spirit. Read more>>

Contact the Clinic
Take a Look
Meet the Doctors

Dr. Luis Ferbeyre, MD Chief Medical Officer & Oncologist
Dr. Luis Ferbeyre earned his Medical Degree from the Medical University of Havana. His early work in oncology focused on Mixed Tumors of the Salivary Glands. Subsequently, he studied Cervicofacial Cancer at the University of Paris and furthered his expertise in Head and Neck Cancer at the National Institute of Oncology and Radiology.
In addition to his specialized studies, Dr. Ferbeyre has contributed to research on the Genetic and Molecular Basis of Cancer and delved into Reconstructive Oncological Surgery for the Head and Neck. He has 31 peer-reviewed articles to his name and has been actively involved in multiple clinical trials.
Professionally, Dr. Ferbeyre is affiliated with the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology.

Dr. Matt Halpert, CEO
Dr. Matthew Halpert earned his doctorate at the University of Alabama-Birmingham (UAB) and then spent 10 years at Baylor College of Medicine in Houston as a Cancer Immunologist. During his research, Dr. Halpert published research in some of the most prestigious peer-reviewed journals, has been cited over 300 hundred times, and became one of the leading experts in regard to cutting-edge cancer immunotherapy.
Additionally, he has founded a cancer-focused charity called Cancer Cures 4 Kids and Diakonos Research, which is currently studying its revolutionary Dendritic Cell Treatment in multiple FDA clinical trials.
In 2021, Dr. Halpert left Baylor College of Medicine to found the Immunocine Cancer Center, which leverages the Dendritic Cell Treatment currently being studied by the FDA. His singular goal in this effort is to provide this revolutionary cancer immunotherapy to patients that cannot wait for treatment.
Conditions Treated
- All types of solid Cancers – Using a novel process replicating a viral infection, Immunocine’s unique treatment initiates a rapid and aggressive immune response against cancer cells throughout the body